Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFINE follow-up study of anacetrapib after prior treatment
2007-005839-28Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis and atherosclerotic disease comparing Anacetrapib + statin with Placebo + statin (2 arms). Primary endpoint: Safety and tolerability of anacetrapib 100 mg. Started Feb 2008; status: completed.
02
Drugs
anacetrapib
03
Conditions
coronary arteriosclerosisatherosclerotic disease
Beyond the preview
Go deeper on 2007-005839-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005839-28.